timothy sykes logo

Stock News

NeurAxis Inc.’s New Path in VA: What This Means

Bryce TuoheyAvatar
Written by Bryce Tuohey Reviewed by Tim Sykes Fact-checked by Matt Monaco
Updated 12/19/2025, 9:19 am ET 12/19/2025, 9:19 am ET | 5 min 5 min read
NeurAxis Inc.’s New Path in VA: What This Means Thumbnail

Neuraxis Inc. stocks have been trading up by 19.44 percent following FDA clearance and promising clinical trial results.

Candlestick Chart

Live Update At 09:18:37 EST: On Friday, December 19, 2025 Neuraxis Inc. stock [NYSE American: NRXS] is trending up by 19.44%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Financial Overview and Key Metrics

As millionaire penny stock trader and teacher Tim Sykes, says, “Be patient, don’t force trades, and let the perfect setups come to you.” This advice is crucial when navigating the volatile world of trading. Successful traders understand the importance of timing and discipline, knowing that impulsive decisions can lead to costly mistakes. By waiting for the ideal conditions, they increase their chances of making profitable trades and achieving long-term success.

NeurAxis’s recent journey through the financial landscape reveals both opportunities and challenges that pepper its path. In its earnings report, the revenue stood a hair above $2.69M, a testament to the company’s substantial strides. Yet, a closer look uncovers a net loss from continuous operations peaking at $2.12M. Achieving profitability is ambitious but not outside their realm, thanks to their increased presence in the medical sector. This does raise eyebrows, as costs weigh heavily, evident from the general and admin expenses reaching $1.88M.

When diving into their financial ratios, certain red flags raise attention. Their ebitda margin is a staggering negative 272.8%, and profit margins remain underwater, suggesting a dire need for optimization. Their current ratio provides a sliver of hope, as it hovers at 1.6, showing an ability to meet short-term liabilities.

Evaluating the balance sheet, total assets amount to $5.77M, dominated by cash reserves sky-high at $4.37M, granting them room for maneuver. Nonetheless, with total liabilities creeping up to $3.49M, stakeholders may be antsy. It seems a delicate balance of potential and peril entwines NeurAxis’s current financial footing.

Taking Apart the Market Movement

Intraday and historical trading data paint a picture akin to a turbulent yet somewhat promising seascape. Stock prices fluttered between $2.63 and $2.88 in recent days, suggesting market volatility steered by new contracts and innovative product debuts. Early morning fluctuations reveal that traders battle between optimism over ventures like the Veterans Affairs deal and caution over looming financial thresholds.

The awarded contract with Veterans Affairs is a key driver roiling the stock further. As NeurAxis expands its influence in the VA health system, it builds not only potential revenue streams but also credibility within the sector. The introduction of their non-drug alternative IB-Stim is anticipated to augment market traction, inviting hopeful investors and skeptics alike.

Amidst these narratives, the broader market perception finds itself tiptoeing a fine line — the struggle between swift transformational opportunities and the cumbersome legacy of financial losses. Through this lens, the stock seesaws, reflecting the cycling sentiments and shifting scales of investor attitudes.

More Breaking News

Looking Ahead

The foray into a formidable domain like the VA health system could signify a tipping point for NeurAxis — potentially stretching across future expansions. Yet, there’s a dual-edge fantasy where theoretical growth clashes with current economic strains. Their trove of cash positions them for further improvements and market penetration.

Success hinges on whether NeurAxis can manage these upcoming challenges efficiently. Operating towards reducing hefty expenses while nurturing new revenue streams remains paramount. As millionaire penny stock trader and teacher Tim Sykes says, “It’s not about how much money you make; it’s about how much money you keep.” This perspective underscores the core strategy NeurAxis must adopt in managing its capital allocations and business expenditures. As market participants digest the company’s latest move, a whirlwind of prospects and perils dances before them.

In summary, NeurAxis invites curiosity, casting a web of intrigue around its destiny in the days moving forward. The climb seems towering, yet opportunities abound. Eyes turn eagerly to how this new venture imbued with promise might unfold amidst a backdrop of fiscal hurdles and technological aspiration.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Bryce Tuohey

Mentor and Trainer at StocksToTrade.com, Lead Mentor at Small Cap Rockets and To The Moon Report
Bryce’s first pattern was buying into strength in breakouts. But he noticed when they didn’t work, he took bigger losses. When the OTC market got hot, Bryce learned to dip buy the inevitable panics. He adapted his breakout strategy and now buys consolidation and trend breaks. His goal is to have better risk/reward and get an entry before multi-day listed breakouts.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”